Compare SONO & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SONO | VCEL |
|---|---|---|
| Founded | 2002 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2018 | 1996 |
| Metric | SONO | VCEL |
|---|---|---|
| Price | $14.37 | $35.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $19.67 | ★ $57.75 |
| AVG Volume (30 Days) | ★ 956.5K | 674.2K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | ★ 0.75 | 0.32 |
| Revenue | ★ $1,443,276,000.00 | $276,259,000.00 |
| Revenue This Year | $5.04 | $19.10 |
| Revenue Next Year | $6.53 | $17.95 |
| P/E Ratio | ★ $18.83 | $105.53 |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $7.83 | $28.95 |
| 52 Week High | $19.82 | $45.97 |
| Indicator | SONO | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 59.08 | 58.85 |
| Support Level | $14.12 | $34.26 |
| Resistance Level | $16.02 | $38.48 |
| Average True Range (ATR) | 0.50 | 1.40 |
| MACD | 0.19 | 0.39 |
| Stochastic Oscillator | 83.29 | 98.36 |
Sonos Inc is an audio company dedicated to elevating life through sound, offering a connected platform that brings together music, movies, stories, and conversations. Its portfolio includes home theater speakers, components, plug-in and portable speakers and headphones, known for exceptional sound, thoughtful design, ease of use and seamless access to audio content. Its partner products and other revenue categories include accessories for home integration, such as custom-designed stands, mounts, and shelving units, along with partnerships for architectural speakers and automotive sound systems, as well as licensing, advertising revenue, and subscription-based services. The company operates in the United States and other countries, with the majority of revenue coming from the United States.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.